Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Drug Therapy
  4. Volume 20, Issue 1
  5. Article
Volume 20, Issue 1
  • ISSN: 1574-8855
  • E-ISSN: 2212-3903

Abstract

One of the classes of injective antidiabetic agents includes Glucagon-like peptide-1 receptor agonists (GLP-1RA) which ameliorate glycemia and numerous atherosclerosis-related factors in individuals prone to Type 2 diabetes mellitus (T2-DM) disorder.

Methods

The review paper targeted the role of GLP-1RA in managing DM. The literature published during the last decades in several data-based searches (PubMed, Scopus, ScienceDirect) was reviewed and compiled the therapeutic uses of GLP-1 RA in the management of DM. In this review, we have discussed GLP-1RA and its role in the management of diabetes mellitus.

Results and Discussion

Disrupted homeostasis marks insulin resistance and β-cell deterioration as two major indications of T2-DM. β-cells failure (~80% of functioning of β-cell) and insulin resistance in the liver and muscles are primarily susceptive to physiological defects. GLP-1RAs if administered for a prolonged period also cause a loss in weight through the activation of receptors of GLP-1 found in hypothalamic satiety centers which control appetite and decrease intake of calories. They not only assist in controlling blood glucose but also improve β- cell function and post–diabetic conditions namely hyperlipidemia, obesity, and hypertension.

Conclusion

It was concluded that GLP-1RA has a new therapeutic approach to the management of DM. Hence, GLP-1RA provides distinctive and innovative evolution for the treatment of T2-DM.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdth/10.2174/0115748855276929231218053337
2024-02-01
2024-11-22

  • From This Site

    /content/journals/cdth/10.2174/0115748855276929231218053337
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. FerrariF. ScheffelR.S. MartinsV.M. SantosR.D. SteinR. Glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus and cardiovascular disease: The past, present, and future.Am. J. Cardiovasc. Drugs202222436338310.1007/s40256‑021‑00515‑434958423
     [Google Scholar]
  2. MüllerT.D. FinanB. BloomS.R. D’AlessioD. DruckerD.J. FlattP.R. FritscheA. GribbleF. GrillH.J. HabenerJ.F. HolstJ.J. LanghansW. MeierJ.J. NauckM.A. Perez-TilveD. PocaiA. ReimannF. SandovalD.A. SchwartzT.W. SeeleyR.J. StemmerK. Tang-ChristensenM. WoodsS.C. DiMarchiR.D. TschöpM.H. Glucagon-like peptide 1 (GLP-1).Mol. Metab.2019307213010.1016/j.molmet.2019.09.01031767182
     [Google Scholar]
  3. PinelliN.R. HurrenK.M. Efficacy and Safety of Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Compared with Exenatide Twice Daily and Sitagliptin in Type 2 Diabetes MellitusA Systematic Review and Meta-Analysis201185086010.1345/aph.1Q024
     [Google Scholar]
  4. CowartK. Oral semaglutide: First-in-class oral glp-1 receptor agonist for the treatment of type 2 diabetes mellitus201947848510.1177/1060028019889064
     [Google Scholar]
  5. AlkheziO.S. AlahmedA.A. AlfayezO.M. AlzumanO.A. AlmutairiA.R. AlmohammedO.A. Comparative effectiveness of glucagon‐like peptide‐1 receptor agonists for the management of obesity in adults without diabetes: A network meta‐analysis of randomized clinical trials.Obes. Rev.2023243e1354310.1111/obr.1354336579723
     [Google Scholar]
  6. SkinnerT.C. JoensenL. ParkinT. Twenty‐five years of diabetes distress research.Diabet. Med.202037339340010.1111/dme.1415731638279
     [Google Scholar]
  7. BerlieH.D. Kale-PradhanP.B. OrzechowskiT. JaberL.A. Mechanisms and potential roles of glucose-lowering agents in COVID-19: A review.Ann. Pharmacother.202155111386139610.1177/106002802199947333657863
     [Google Scholar]
  8. NatarajanJ. Mokoboto-ZwaneS. Health-related quality of life and domain-specific associated factors among patients with type 2 diabetes mellitus in South India.Rev. Diabet. Stud.2022181344110.1900/RDS.2022.18.3435300755
     [Google Scholar]
  9. HurrenK.M. PinelliN.R. Drug-drug interactions with glucagon-like peptide-1 receptor agonists201271071710.1345/aph.1Q583
     [Google Scholar]
  10. SoniaT.A. SharmaC.P. Oral delivery of insulin, 1st edition.United KingdomWoodhead Publishing2014
     [Google Scholar]
  11. UssarS. VienbergS.G. KahnC.R. Receptor antibodies as novel therapeutics for diabetes.Sci. Transl. Med.20113113113ps4710.1126/scitranslmed.300344722174312
     [Google Scholar]
  12. DoumasM. ImprialosΚ. StavropoulosK. ReklouA. SachinidisA. AthyrosV.G. Combination of SGLT-2 inhibitors and GLP-1 receptor agonists: Potential benefits in surrogate and hard endpoints.Curr. Pharm. Des.201824171879188610.2174/138161282466618060411365329865997
     [Google Scholar]
  13. ScheenA.J. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.Diabetes Metab.201945211012110.1016/j.diabet.2018.10.00330477733
     [Google Scholar]
  14. NauckM.A. QuastD.R. WefersJ. MeierJ.J. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art.Mol. Metab.20214610110210.1016/j.molmet.2020.10110233068776
     [Google Scholar]
  15. WillardF.S. DourosJ.D. GabeM.B.N. ShowalterA.D. WainscottD.B. SuterT.M. CapozziM.E. van der VeldenW.J.C. StutsmanC. CardonaG.R. UrvaS. EmmersonP.J. HolstJ.J. D’AlessioD.A. CoghlanM.P. RosenkildeM.M. CampbellJ.E. SloopK.W. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.JCI Insight2020517e14053210.1172/jci.insight.14053232730231
     [Google Scholar]
  16. MeloniA.R. DeYoungM.B. LoweC. ParkesD.G. GLP ‐1 receptor activated insulin secretion from pancreatic β‐cells: Mechanism and glucose dependence.Diabetes Obes. Metab.2013151152710.1111/j.1463‑1326.2012.01663.x22776039
     [Google Scholar]
  17. GilbertM.P. PratleyR.E. GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: Review of head-to-head clinical trials.Front. Endocrinol.20201117810.3389/fendo.2020.0017832308645
     [Google Scholar]
  18. StarkJ.E. ColeJ.L. GhazarianR.N. KlassM.J. Impact of glucagon-like peptide-1 receptor agonists (GLP-1RA) on food content during esophagogastroduodenoscopy (EGD)Ann Pharmacother.202156892292610.1177/10600280211055804
     [Google Scholar]
  19. DeaconC.F. MannucciE. AhrénB. Glycaemic efficacy of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors as add‐on therapy to metformin in subjects with type 2 diabetes—a review and meta analysis.Diabetes Obes. Metab.201214876276710.1111/j.1463‑1326.2012.01603.x22471248
     [Google Scholar]
  20. CarrA.L.J. PerryD.J. LynamA.L. ChamalaS. FlaxmanC.S. SharpS.A. FerratL.A. JonesA.G. BeeryM.L. JacobsenL.M. WasserfallC.H. Campbell-ThompsonM.L. KusmartsevaI. PosgaiA. SchatzD.A. AtkinsonM.A. BruskoT.M. RichardsonS.J. ShieldsB.M. OramR.A. Histological validation of a type 1 diabetes clinical diagnostic model for classification of diabetes.Diabet. Med.202037122160216810.1111/dme.1436132634859
     [Google Scholar]
  21. ModelJ.F.A. RochaD.S. FagundesA.C. VinagreA.S. Physiological and pharmacological actions of glucagon like peptide-1 (GLP-1) in domestic animals.Vet. Anim. Sci.20221610024510.1016/j.vas.2022.10024535372707
     [Google Scholar]
  22. DruckerD.J. Mechanisms of action and therapeutic application of glucagon-like peptide-1.Cell Metab.201827474075610.1016/j.cmet.2018.03.00129617641
     [Google Scholar]
  23. ZhaoF. ZhouQ. CongZ. HangK. ZouX. ZhangC. ChenY. DaiA. LiangA. MingQ. WangM. ChenL.N. XuP. ChangR. FengW. XiaT. ZhangY. WuB. YangD. ZhaoL. XuH.E. WangM.W. Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors.Nat. Commun.2022131105710.1038/s41467‑022‑28683‑035217653
     [Google Scholar]
  24. DruckerD.J. GLP-1 physiology informs the pharmacotherapy of obesity.Mol. Metab.20225710135110.1016/j.molmet.2021.10135134626851
     [Google Scholar]
  25. DeFronzoR.A. Combination therapy with GLP ‐1 receptor agonist and SGLT2 inhibitor.Diabetes Obes. Metab.201719101353136210.1111/dom.1298228432726
     [Google Scholar]
  26. ShomaliM.E. ØrstedD.D. CannonA.J. Efficacy and safety of liraglutide, a once‐daily human glucagon‐like peptide‐1 receptor agonist, in African‐American people with Type 2 diabetes: A meta‐analysis of sub‐population data from seven phase III trials.Diabet. Med.201734219720310.1111/dme.1318527412701
     [Google Scholar]
  27. CornellS. A review of GLP‐1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once‐weekly agents.J. Clin. Pharm. Ther.202045S1Suppl. 1172710.1111/jcpt.1323032910490
     [Google Scholar]
  28. ShaeferC.F.Jr KushnerP. AguilarR. User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists.Postgrad. Med.2015127881882610.1080/00325481.2015.109029526371721
     [Google Scholar]
  29. DoyleM. EganJ. Mechanisms of action of GLP-1 in the pancreas.Pharmacol. Ther.2007113354693
     [Google Scholar]
  30. CarlessiR. ChenY. RowlandsJ. CruzatV.F. KeaneK.N. EganL. MamotteC. StokesR. GuntonJ.E. BittencourtP.I.H. NewsholmeP. GLP-1 receptor signalling promotes β-cell glucose metabolism via mTOR-dependent HIF-1α activation.Sci. Rep.201771266110.1038/s41598‑017‑02838‑228572610
     [Google Scholar]
  31. TrautmannM.E. VoraJ. Use of glucagon‐like peptide‐1 receptor agonists among individuals on basal insulin requiring treatment intensification.Diabet. Med.201835669470610.1111/dme.1361029478255
     [Google Scholar]
  32. BurgmaierM. HeinrichC. MarxN. Cardiovascular effects of GLP‐1 and GLP‐1‐based therapies: Implications for the cardiovascular continuum in diabetes?Diabet. Med.201330328929910.1111/j.1464‑5491.2012.03746.x22804451
     [Google Scholar]
  33. StephenA. B. WyshamC.H. GLP-1 receptor agonists in the treatment of type 2 diabetes: Role and clinical experience to date.Postgrad. Med.2020132sup231410.1080/00325481.2020.179809932815454
     [Google Scholar]
  34. AlatorreC. Fernández LandóL. YuM. BrownK. MontejanoL. JuneauP. ModyR. SwindleR. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon‐like peptide‐1 receptor agonists: H igher adherence and persistence with dulaglutide compared with once‐weekly exenatide and liraglutide.Diabetes Obes. Metab.201719795396110.1111/dom.1290228181725
     [Google Scholar]
  35. OvergaardR.V. LindbergS.Ø. ThielkeD. Impact on HbA1c and body weight of switching from other GLP‐1 receptor agonists to semaglutide: A model‐based approach.Diabetes Obes. Metab.2019211435110.1111/dom.1347930047216
     [Google Scholar]
  36. RothC.L. PerezF.A. WhitlockK.B. ElfersC. YanovskiJ.A. ShoemakerA.H. AbuzzahabM.J. A phase 3 randomized clinical trial using a o nce‐weekly glucagon‐like peptide‐1 receptor agonist in adolescents and young adults with hypothalamic obesity.Diabetes Obes. Metab.202123236337310.1111/dom.1422433026160
     [Google Scholar]
  37. ToféS. ArgüellesI. MenaE. SerraG. CodinaM. UrgelesJ.R. GarcíaH. PeregV. Real‐world GLP‐1 RA therapy in type 2 diabetes: A long‐term effectiveness observational study.Endocrinol. Diabetes Metab.201921e0005110.1002/edm2.5130815578
     [Google Scholar]
  38. RazaviM. WeiY.Y. RaoX.Q. ZhongJ.X. DPP-4 inhibitors and GLP-1RAs: Cardiovascular safety and benefits.Mil. Med. Res.2022914510.1186/s40779‑022‑00410‑235986429
     [Google Scholar]
  39. XueX. RenZ. ZhangA. YangQ. ZhangW. LiuF. Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: A systemic review of randomised controlled trials.Int. J. Clin. Pract.201670864965610.1111/ijcp.1284727456750
     [Google Scholar]
  40. PatelD. Glycaemic and non‐glycaemic efficacy of once‐weekly GLP‐1 receptor agonists in people with type 2 diabetes.J. Clin. Pharm. Ther.202045S1Suppl. 1284210.1111/jcpt.1322432910489
     [Google Scholar]
  41. PottsJ.E. GrayL.J. BradyE.M. KhuntiK. DaviesM.J. BodicoatD.H. The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: A systematic review and mixed treatment comparison meta-analysis.PLoS One2015106e012676910.1371/journal.pone.012676926121478
     [Google Scholar]
  42. WuQ. LiD. HuangC. ZhangG. WangZ. LiuJ. YuH. SongB. ZhangN. LiB. ChuX. Glucose control independent mechanisms involved in the cardiovascular benefits of glucagon-like peptide-1 receptor agonists.Biomed. Pharmacother.202215311351710.1016/j.biopha.2022.11351736076602
     [Google Scholar]
  43. MirabelliM. ChiefariE. TocciV. CaroleoP. GiulianoS. GrecoE. LuqueR.M. PuccioL. FotiD.P. AversaA. BrunettiA. Clinical effectiveness and safety of once-weekly GLP-1 receptor agonist dulaglutide as add-on to metformin or metformin plus insulin secretagogues in obesity and type 2 diabetes.J. Clin. Med.202110598510.3390/jcm1005098533801192
     [Google Scholar]
  44. O’NeilP.M. BirkenfeldA.L. McGowanB. MosenzonO. PedersenS.D. WhartonS. CarsonC.G. JepsenC.H. KabischM. WildingJ.P.H. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: A randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.Lancet20183921014863764910.1016/S0140‑6736(18)31773‑230122305
     [Google Scholar]
  45. IshigakiY. StrizekA. AranishiT. AraiN. ImaokaT. CaiZ. MaegawaH. Glucagon-like peptide-1 receptor agonist utilization in type 2 diabetes in Japan: A retrospective database analysis (JDDM 57).Diabetes Ther.202112134536110.1007/s13300‑020‑00977‑w33300091
     [Google Scholar]
  46. Zimner RapuchS. DivinoV. NorrbackaK. BoyeK. LebrecJ. RosilioM. DeKovenM. GuerciB. Treatment patterns and persistence with GLP-1 RA treatments among patients with type 2 diabetes in france: A retrospective cohort analysis.Diabetes Ther.20211251553156710.1007/s13300‑021‑01055‑533864629
     [Google Scholar]
  47. BaileyC.J. FlattP.R. ConlonJ.M. An update on peptide-based therapies for type 2 diabetes and obesity.Peptides202316117093910.1016/j.peptides.2023.17093936608818
     [Google Scholar]
  48. HanefeldM. SchaperF. Medical prevention of type 2 diabetes - If lifestyle intervention is not enough Klinikarzt200837
     [Google Scholar]
  49. RentzeperiE. PegiouS. KoufakisT. GrammatikiM. KotsaK. Sex differences in response to treatment with glucagon-like peptide 1 receptor agonists: Opportunities for a tailored approach to diabetes and obesity care.J. Pers. Med.202212345410.3390/jpm1203045435330453
     [Google Scholar]
  50. SalmenT. BobircaF.T. BicaI.C. MihaiD.A. PopC. StoianA.P. The safety profile of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists in the standard of care treatment of type 2 diabetes mellitus.Life202313383910.3390/life1303083936983994
     [Google Scholar]
  51. LuoJ. FeldmanR. Callaway KimK. RothenbergerS. KorytkowskiM. HernandezI. GelladW.F. Evaluation of out-of-pocket costs and treatment intensification with an SGLT2 inhibitor or GLP-1 RA in patients with type 2 diabetes and cardiovascular disease.JAMA Netw. Open202366e231788610.1001/jamanetworkopen.2023.1788637307000
     [Google Scholar]
  52. YangC.Y. ChenY.R. OuH.T. KuoS. Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: A real-world study and systematic review.Cardiovasc. Diabetol.20212012110.1186/s12933‑020‑01211‑433468131
     [Google Scholar]
  53. WilkeT. MuellerS. FuchsA. KaltoftM.S. KipperS. CelM. Diabetes-related effectiveness and cost of liraglutide or insulin in german patients with type 2 diabetes: A 5-year retrospective claims analysis.Diabetes Ther.202011102357237010.1007/s13300‑020‑00903‑032876862
     [Google Scholar]
  54. SikiricaM. MartinA. WoodR. LeithA. PiercyJ. HigginsV. Reasons for discontinuation of GLP1 receptor agonists: Data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes.Diabetes Metab. Syndr. Obes.20171040341210.2147/DMSO.S14123529033597
     [Google Scholar]
  55. TrujilloJ.M. NufferW. SmithB.A. GLP-1 receptor agonists: An updated review of head-to-head clinical studies.Ther. Adv. Endocrinol. Metab.20211210.1177/204201882199732033767808
     [Google Scholar]
  56. NgE. ShawJ.E. WoodA. Maple-BrownL.J. HareM.J.L. Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes.Aust. J. Gen. Pract.202251751351810.31128/AJGP‑07‑21‑605735773162
     [Google Scholar]
  57. DubourgJ. FouquerayP. QuinslotD. GrouinJ.M. KakuK. Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes ( TIMES 2): A 52‐week, open‐label, multicentre phase 3 trial.Diabetes Obes. Metab.202224460961910.1111/dom.1461334866306
     [Google Scholar]
  58. TranK.L. ParkY.I. PandyaS. MuliyilN.J. JensenB.D. HuynhK. NguyenQ.T. Overview of glucagon-like peptide-1 receptor agonists for the treatment of patients with type 2 diabetesAm. Heal. Drug Benefits. 201710178
     [Google Scholar]
  59. DaviesM.J. BergenstalR. BodeB. KushnerR.F. LewinA. SkjøthT.V. AndreasenA.H. JensenC.B. DeFronzoR.A. ValensiP. LevyM. BenabdallahS. SerusclatP. CourregesJ.P. GouetD. ClavelS. CariouB. TylerK. HanefeldM. JordanR. MilekK. RoseL. SauterJ. SteindorfJ. WendishU. RudofskyG. ErlingerR. Harman-BoehmI. MosenzonO. CohenJ. KarasikA. MinuchinO. SnymanH.H. KomatiS.M. NaikerP. LombaardJ.J. PodgorskiG. SalehM.F. MuñozM. ParreñoL.D.T. GarcíaS.D. EstebanB.M. FernándezM.R. PérezA.M.S. BurgueraB. VázquezC. HemmingssonJ.U. EizykE. RautioA. NorrbyA. JasinskaE. ComlekciA. GokceC. GulK. MansellP. JohnsonA.B. MillwardA. BilousR. CollierD.A. HitmanG. MaxwellT. JosephF. DavisM. HolmesP. ThekkepayS. ParkA. CapehornM. TaheriS. ArodaV.R. BlevinsT.C. BodeB.W. BresslerP. BristolP.E. CheungD. BergenstalR.M. Fitz-PatrickD. FurlongK. GormanD. HollanderP. HuffmanD. KwonE. LipetzR.S. LucasK.J. PollockJ. Rivera-ColonL. RosenstockJ. SalazarH.A. SelamJ.L. ShelmetJ. SimonH.J. SolerN.G. SugimotoD. TougerS. WynneA. LeichterS.B. KleinE.J. KolettisE.M. LynnL. LaneJ.T. BaysH.E. Granda-RodriguezR. BuschR.S. CannonK. ChangA. ChappelC.M. DowJ.T. EarlJ.K. ElinoffV. FarmerM.V. WoolleyJ.H. GonteW.S. KleinS. LaneW.S. LangJ.A. LermanS. LubinB. MartinP.A. McNeillR.E. MillsR.E. MurrayA.V. MyersL. BaoS. OrrR. PowellS. ReedJ.C. RhudyJ. SawayW. SofleyW. TurnerM. WelchM. WilsonJ. ZimmermanT.S. NN8022-1922 Study Group Efficacy of liraglutide for weight loss among patients with type 2 diabetes.JAMA2015314768769910.1001/jama.2015.967626284720
     [Google Scholar]
  60. TrujilloJ.M. NufferW. Albiglutide.Ann. Pharmacother.201448111494150110.1177/106002801454580725136065
     [Google Scholar]
  61. ThompsonA.M. TrujilloJ.M. Dulaglutide.Ann. Pharmacother.201549335135910.1177/106002801456418025565404
     [Google Scholar]
  62. AndersonS.L. TrujilloJ.M. Lixisenatide in type 2 diabetes: Latest evidence and clinical usefulness.Ther. Adv. Chronic Dis.20167141710.1177/204062231560931226770666
     [Google Scholar]
  63. LinnebjergH. ParkS. KothareP.A. TrautmannM.E. MaceK. FinemanM. WildingI. NauckM. HorowitzM. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes.Regul. Pept.20081511-312312910.1016/j.regpep.2008.07.00318675854
     [Google Scholar]
  64. BuseJ.B. HenryR.R. HanJ. KimD.D. FinemanM.S. BaronA.D. Exenatide-113 Clinical Study Group Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.Diabetes Care200427112628263510.2337/diacare.27.11.262815504997
     [Google Scholar]
  65. KimD. MacConellL. ZhuangD. KothareP.A. TrautmannM. FinemanM. TaylorK. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.Diabetes Care20073061487149310.2337/dc06‑237517353504
     [Google Scholar]
  66. YousefC.C. ThomasA. MatarM.A. GhandouraL. AldossaryI. AlmuhannaS.M. AlhussainF. AL BisherF.B. AljohaniR.M. BalubaidA.N. NouhM.I. AlmurashiA. AlAmoudiR. Liraglutide effects on glycemic control and weight in patients with type 2 diabetes Mellitus: A real-world, observational study and brief narrative review.Diabetes Res. Clin. Pract.202117710887110.1016/j.diabres.2021.10887134052248
     [Google Scholar]
  67. JanssenL.G.M. NahonK.J. BrackéK.F.M. van den BroekD. SmitR. Sardjoe MishreA.S.D. KoorneefL.L. Martinez-TellezB. BurakiewiczJ. KanH.E. van VeldenF.H.P. Pereira Arias-BoudaL.M. de Geus-OeiL.F. BerbéeJ.F.P. JazetI.M. BoonM.R. RensenP.C.N. Twelve weeks of exenatide treatment increases [18F]fluorodeoxyglucose uptake by brown adipose tissue without affecting oxidative resting energy expenditure in nondiabetic males.Metabolism202010615416710.1016/j.metabol.2020.15416731982480
     [Google Scholar]
  68. Rajamand EkbergN. BodholdtU. CatarigA.M. CatrinaS.B. GrauK. HolmbergC.N. KlangerB. KnudsenS.T. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study.Prim. Care Diabetes202115587187810.1016/j.pcd.2021.06.00834183269
     [Google Scholar]
  69. ChenX. XuY. ZhangJ. ShaoS. DuanY. LiuP. ShenL. ZhangJ. ZengJ. LinM. ZhaoS. MaJ. ZhaoT. HuJ. LiaoY. ChenX. HuS. XueY. ZengZ. HeW. LiuZ. LiW. LiuL. YinP. YuX. Exenatide twice daily plus glargine versus aspart 70/30 twice daily in patients with type 2 diabetes with inadequate glycemic control on premixed human insulin and metformin.Endocr. Pract.202127879079710.1016/j.eprac.2021.03.01533831552
     [Google Scholar]
  70. Di DalmaziG. ColuzziS. BaldassarreM.P.A. SorboS.E. Dell’AquilaS. FeboF. GinestraF. GrazianoG. RossiM.C. ConsoliA. FormosoG. Exenatide once weekly: Effectiveness, tolerability, and discontinuation predictors in a real-world setting.Clin. Ther.202042917381749.e110.1016/j.clinthera.2020.07.00232753164
     [Google Scholar]
  71. Philis-TsimikasA. WyshamC.H. HardyE. HanJ. IqbalN. Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: An open-label extension of the DURATION-1 study.J. Diabetes Complications201933322323010.1016/j.jdiacomp.2018.11.01230600137
     [Google Scholar]
  72. BasoloA. BurkholderJ. OsgoodK. GrahamA. BundrickS. FranklJ. PiaggiP. ThearleM.S. KrakoffJ. Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial.Metabolism20188511612510.1016/j.metabol.2018.03.01729596853
     [Google Scholar]
  73. TrautmannM.E. Van GaalL. HanJ. HardyE. Three-year efficacy and safety of exenatide once weekly: A pooled analysis of three trials.J. Diabetes Complications20173191415142210.1016/j.jdiacomp.2017.06.00428669463
     [Google Scholar]
  74. TrautmannM.E. HanJ. RugglesJ. Early pharmacodynamic effects of exenatide once weekly in type 2 diabetes are independent of weight loss: A pooled analysis of patient-level data.Clin. Ther.20163861464147310.1016/j.clinthera.2016.03.03927126504
     [Google Scholar]
  75. KazimM. TrivediN. Addition of dulaglutide for a high-dose insulin requiring patient with type 2 diabetes mellitus: A remarkable response.AACE Clin. Case Rep.201952e142e14510.4158/ACCR‑2018‑019231967020
     [Google Scholar]
/content/journals/cdth/10.2174/0115748855276929231218053337
Loading
Clinical Analysis of Resemblance and Dissimilarities of Glucagon-like Peptide-1 Receptor Agonists: Therapeutic Approach Towards the Management of Diabetes Mellitus
Curr Drug Ther 20, 45 (2025); https://doi.org/10.2174/0115748855276929231218053337
/content/journals/cdth/10.2174/0115748855276929231218053337
/content/journals/cdth/10.2174/0115748855276929231218053337
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): exenatide; GLP-1; incretin mimetics; insulin; type 2 diabetes mellitus; β-cells

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test